Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Operating Leases (2022 - 2025)

Historic Operating Leases for GeneDx Holdings (WGS) over the last 4 years, with Q3 2025 value amounting to $57.2 million.

  • GeneDx Holdings' Operating Leases fell 532.72% to $57.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.2 million, marking a year-over-year decrease of 532.72%. This contributed to the annual value of $60.9 million for FY2024, which is 850.94% down from last year.
  • As of Q3 2025, GeneDx Holdings' Operating Leases stood at $57.2 million, which was down 532.72% from $59.6 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Operating Leases peaked at $69.1 million during Q2 2023, and registered a low of $57.2 million during Q3 2025.
  • For the 4-year period, GeneDx Holdings' Operating Leases averaged around $63.7 million, with its median value being $63.4 million (2022).
  • In the last 5 years, GeneDx Holdings' Operating Leases skyrocketed by 892.78% in 2023 and then plummeted by 1200.39% in 2024.
  • Quarter analysis of 4 years shows GeneDx Holdings' Operating Leases stood at $66.1 million in 2022, then grew by 0.68% to $66.6 million in 2023, then decreased by 8.51% to $60.9 million in 2024, then dropped by 6.18% to $57.2 million in 2025.
  • Its Operating Leases stands at $57.2 million for Q3 2025, versus $59.6 million for Q2 2025 and $59.9 million for Q1 2025.